CLAIMS

1. A compound represented by the formula (I)



(I)

wherein

A is a group represented by the following formula (A1), (A2) or (A3)



(A1)



(A2)



(A3)

B is a 1H-tetrazol-5-yl group or a 2,4-dioxothiazolidin-5-yl group,

X is methylene, an oxygen atom or a sulfur atom,

Y is a single bond or a C6-10 arylene group,

R^{1A} is a hydrogen atom or a C1-6 alkyl group,

R^{2A} and R^{3A} are the same or different and each is a hydrogen atom, a carboxyl group or a C1-6 alkyl group,

R^{4A}, R^{5A} and R^{6A} are the same or different and each is a hydrogen atom or a C1-6 alkyl group, and

R^{7A} is a C1-10 alkyl carbonyl group,

provided that when A is (A2), then B should be a 2,4-dioxothiazolidin-5-yl group,

or a pharmacologically acceptable salt thereof or an ester thereof.

2. The compound of claim 1, wherein B is a 1H-tetrazol-5-yl group, or a pharmacologically acceptable salt thereof or an ester thereof.

3. The compound of claim 1 or 2, wherein Y is a C6-10 arylene group, or a pharmacologically acceptable salt thereof or an ester thereof.

4. The compound of any of claims 1 to 3, wherein Y is a phenylene group, or a pharmacologically acceptable salt thereof or an ester thereof.

5. The compound of claim 1, wherein B is a 2,4-dioxothiazolidin-5-yl group, or a pharmacologically acceptable salt thereof or an ester thereof.

6. The compound of claim 1, wherein A is a group represented by (A1), and B is a 1H-tetrazol-5-yl group, or a pharmacologically acceptable salt thereof or an ester thereof.

7. The compound of claim 1, wherein A is a group represented by (A2), and B is a 2,4-dioxothiazolidin-5-yl group, or a pharmacologically acceptable salt thereof or an ester thereof.

8. A compound represented by the formula (IA3)



(IA3)

wherein

B is a 1H-tetrazol-5-yl group or a 2,4-dioxothiazolidin-5-yl group,

Y is a single bond or a C6-10 arylene group, and

R^{7A} is a C1-10 alkyl carbonyl group,

or a pharmacologically acceptable salt thereof or an ester thereof.

9. The compound of claim 8, wherein B is a 1H-tetrazol-5-yl group, or a pharmacologically acceptable salt thereof or an ester thereof.

10. A compound selected from the group consisting of 3-[N-[[4-[2-(1H-tetrazol-5-yl)phenyl]phenyl]methyl]-N-pentanoylamino]benzoic acid,
3-[N-[[4-[2-(1H-tetrazol-5-yl)phenyl]phenyl]methyl]-N-butanoylamino]benzoic acid,
3-[N-[[4-[2-(1H-tetrazol-5-yl)phenyl]phenyl]methyl]-N-heptanoylamino]benzoic acid,
2-oxo-3-propyl-1-[[4-[2-(1H-tetrazol-5-yl)phenyl]phenyl]methyl]-1,3,4-trihydroquinoline-7-carboxylic acid and
5-[4-[(2-ethyl-5,7-dimethylimidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-1,3-thiazolidine-2,4-dione,
or a pharmacologically acceptable salt thereof or an ester thereof.

11. 3-[N-[4-(2,4-Dioxothiazolidin-5-yl)benzyl]-N-pentanoylamino]benzoic acid, 3-[N-[[4-[2-(1H-tetrazol-5-yl)phenyl]phenyl]methyl]-N-octanoylamino]benzoic acid, or a pharmacologically acceptable salt thereof or an ester thereof.

12. A medicament comprising the compound of any of claims 1 to 11, or a pharmacologically acceptable salt thereof or an ester thereof.

13. An inhibitor of AGEs formation, which comprises the compound of any of claims 1 to 11, or a pharmacologically acceptable salt thereof or an ester thereof.

14. A pharmaceutical composition for the prophylaxis or

treatment of diabetic complication, which comprises the compound of any of claims 1 to 11, or a pharmacologically acceptable salt thereof or an ester thereof.

15. A pharmaceutical composition for the prophylaxis or treatment of diabetic nephropathy, which comprises the compound of any of claims 1 to 11, or a pharmacologically acceptable salt thereof or an ester thereof.

16. Use of the compound of any of claims 1 to 11, or a pharmacologically acceptable salt thereof or an ester thereof, for the production of a medicament for the prophylaxis or treatment of diabetic complication.

17. Use of the compound of any of claims 1 to 11, or a pharmacologically acceptable salt thereof or an ester thereof, for the production of an inhibitor of AGEs formation.

18. Use of the compound of any of claims 1 to 11, or a pharmacologically acceptable salt thereof or an ester thereof, for the production of a pharmaceutical composition for the prophylaxis or treatment of diabetic complication.

19. Use of the compound of any of claims 1 to 11, or a pharmacologically acceptable salt thereof or an ester thereof, for the production of a pharmaceutical composition for the prophylaxis or treatment of diabetic nephropathy.

20. A method of inhibiting AGEs formation in a warm-blooded animal, which comprises administering a pharmacological effective amount of the compound of any of claims 1 to 11, or a pharmacologically acceptable salt thereof or an ester thereof, to the warm-blooded animal.

21. A method of preventing or treating diabetic complication in a warm-blooded animal, which comprises administering a pharmacological effective amount of the compound of any of claims 1 to 11, or a pharmacologically acceptable salt thereof or an ester thereof, to the warm-blooded animal.

22. A commercial package comprising the medicament of claim 12, and a written matter associated therewith, the written matter stating that the medicament can or should be used for the prophylaxis or treatment of diabetic nephropathy.

23. A commercial package comprising the inhibitor of claim 13, and a written matter associated therewith, the written matter stating that the inhibitor can or should be used for inhibiting AGEs formation.

24. A commercial package comprising the pharmaceutical composition of claim 14, and a written matter associated therewith, the written matter stating that the pharmaceutical composition can or should be used for the prophylaxis or treatment of diabetic complication.

25. A commercial package comprising the pharmaceutical composition of claim 15, and a written matter associated therewith, the written matter stating that the pharmaceutical composition can or should be used for the prophylaxis or treatment of diabetic nephropathy.